Amarantus Bioscience Holdings, Inc. · OTC:AMBS
Amarantus Bioscience — Corporate Update (April 2015)
23 slides from Amarantus Bioscience's corporate update, Apr 9, 2015
Slide 1: Business Update Conference Call
1 Developing clinical - stage products in neurology, psychiatry and orphan indications BUSINESS UPDATE CONFERENCE CALL April 9, 2015 OTCQB: AMBS
Slide 2: Forward-Looking Statements
This presentation contains “ forward - looking statements ” within the meaning of the “ safe - harbor ” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Comp
Slide 3: Agenda
3 Agenda • INTRODUCTION • FINANCIAL REVIEW AND OUTLOOK • THERAPEUTICS DIVISION REVIEW • DIAGNOSTICS DIVISION REVIEW • 2015 EXPECTED MILESTONES • Q&A
Slide 4: Focused Execution Delivers Rich Pipeline
Focused Execution Delivers Rich Pipeline 4 Asset Pre - Clinical Phase 1 Phase 2 Phase 3 Value Driving Milestone Potential strategic transaction in 2015 Eltoprazine: PD - LID Phase 2b program clinical data in 2016 ESS*: 50+% TBSA Severe Burns Phase 2 clinical data in 2016 MANF: Retinitis Pigmentosa (
Slide 5: A Year of Building Solid Fundamentals
5 A Year of Building Solid Fundamentals Therapeutics Division • Eltoprazine platform establishes neurology/psychiatry pipeline • Opportunistic potential acquisition of Cutanogen Corporation diversifies pipeline with clinical - stage, ultra - orphan program • MANF orphan ocular strategy establishes f
Slide 6: Financial Review and Outlook
Financial Review and Outlook 6
Slide 7: Path to Eventual Up-listing
Path to Eventual Up - listing 7 Access to Lincoln Park Capital Facility Series E primarily for ESS and MSPrecise transactions Exploring funding options to execute plan Eventual Listing on National Exchange Strategic Transaction to fuel pipeline
Slide 8: Therapeutics Division Review
Therapeutics Division Review 8
Slide 9: Therapeutics Division: Milestone Achievements
Therapeutics Division: Milestone Achievements Eltoprazine x Published Phase 2a clinical study results in BRAIN for the treatment of PD - LID x Opened an IND application with the neurology division of the FDA to advance Eltoprazine into Phase 2b clinical studies MANF x Received Orphan Drug Designatio
Slide 10: Eltoprazine Ready to Commence Phase 2b Program in PD-LID
Eltoprazine Ready to Commence Phase 2b Program in PD - LID Exceptional safety profile: – Administered to 682 humans (volunteers and patients) – Up to two years dosing studied by Solvay (now Abbvie) Clinical Indications – Parkinson’s disease (PD) L - Dopa Induced Dyskinesia (LID): • Open IND with Pha
Slide 11: Eltoprazine: PD Market Opportunity
Eltoprazine: PD Market Opportunity • 1M+ Americans patients have PD • 60 - 80% diagnosed with PD - LID • 60,000 new diagnoses annually • 3M million by 2032 • Total cost to U.S.: $25B • Key unmet medical need: LID – Other PD symptoms addressed: Cognition, other psychiatric measures • Market opportuni
Slide 12: MANF has "Blue-Sky" Potential
MANF has “Blue - Sky” Potential Preclinical Programs – Potential paradigm shift in cell protection and restoration – $ Multi - billion opportunity – Lead programs in orphan ocular indications • Retinitis Pigmentosa (orphan granted) • Retinal artery occlusion (potential orphan) • Wolfram’s (potential
Slide 13: Cutanogen Acquisition Could Add Significant Value
Cutanogen Acquisition Could Add Significant Value • Autologous, skin graft replacement for 50 + % TBSA severe burns • Biologics/drug regulatory pathway in office of combination products • Orphan Drug Designation received in 2012 • Active IND as of May 2014 • Partially funded by US Gov’t grant : AFIR
Slide 14: Amarantus Diagnostics
Amarantus DIAGNOSTICS
Slide 15: Diagnostic Candidates
Diagnostic Candidates Clinical Validation Analytical Performance Commercialization LymPro Test ® MSPrecise ® Georgetown Assays* Alzheimer's Disease Multiple Sclerosis Alzheimer’s Disease Exploring Strategic Options for Monetization Preparing for “Exit Strategy” to Unlock Value 15 *Upon exercise of e
Slide 16: Diagnostics Division: Pipeline Achievements
Diagnostics Division: Pipeline Achievements LymPro Test ® • Presented positive LymPro data at the 12 th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders • Established the Company’s first Investigational Use Only (IUO) Alzheimer’s biomarker services
Slide 17: LymPro Status and BD Strategy
• Currently available as IUO for clinical trials • Completing multivariate analysis to support CLIA pathway • Business development initiative commenced 4Q 2014 • Moving forward with robust BD strategy – Recent hiring of Ravi Kiron bolsters capabilities LymPro Status and BD Strategy 17 Commence due d
Slide 18: MSPrecise: Compelling Commercial Opportunity
MSPrecise: Compelling Commercial Opportunity • Highly differentiated lead diagnostic that will significantly improve the diagnostic paradigm in MS as an adjunct to standard of care (oligloclonal banding) • Peak sales potential in North America of ~$300M • ~200 US MS clinics allowing for economical s
Slide 19: Positioning Division as Potential Market Leader in Neurodiagnostics
• MSPrecise product ready to initiate commercialization process – Strong pharmacoeconomic rationale for reimbursement – CLIA commercialization pathway being prosecuted to deliver in 2015 – $300 million peak sales potential in US • Positioned as leading Alzheimer’s blood - based biomarker service pro
Slide 20: Significant Steps Taken to Prepare for Exit
20 Significant Steps Taken to Prepare for “Exit” x Retained an executive search firm to identify a Chief Executive Officer for the Diagnostics division x Retained Ravi Kiron, Ph.D. as Senior Vice President of Business Development x Promoted Colin Bier, Ph.D., to Chief Development Officer to oversee
Slide 21: Exit Strategy Accelerated as a Priority
21 “Exit” Strategy Accelerated as a Priority • Evaluating strategic options for the diagnostics business unit • Potential options under consideration – Potential sale of the division for cash (and maintain a royalty) – IPO or RTO – License the technologies to a third party – Evaluate a combination o
Slide 22: 2015 Expected Milestones
2015 Expected Milestones • Initiate Phase 2 b clinical study of Eltoprazine in PD - LID in 2 Q 2015 • Complete enrollment of Phase 2 b clinical study of Eltoprazine in PD - LID • Complete acquisition of Cutanogen – Initiate Phase 2 study of ESS mid - year 2015 • MANF progression towards first - in -
Slide 23: Developing clinical-stage products in neurology, psychiatry and orphan indications
23 Developing clinical - stage products in neurology, psychiatry and orphan indications OTCQB: AMBS
Amarantus Bioscience Holdings — Corporate Update (April 2015) on 6ix